ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer

New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients […]

read more

ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]

read more

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]

read more

ASCO GU 2019: Nivolumab monotherapy for non-clear cell renal cell carcinoma

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Nicholas Vogelzang of the Comprehensive Cancer Centers of Nevada, Las Vegas, and colleagues presented updated safety data and efficacy of nivolumab in patients with non-clear cell renal cell carcinoma (RCC) in […]

read more

ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Rini from the Cleveland Clinic Taussig Cancer Institute presented the results from a phase 3 clinical trial (TIVO-3) to compare the efficacy and safety of tivozanib to sorafenib in patients […]

read more

ASCO GU 2019: Patient perspectives on cytoreductive nephrectomy after CARMENA

The following survey assessed patient views related to cytoreductive nephrectomy following publication of the results of the CARMENA trial, and were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The survey found that overall survival should not be overestimated as the most important aim […]

read more

ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

Results from this trial for patients with non-clear cell renal cell carcinoma (RCC) or sarcomatoid RCC were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The combination of atezolizumab and bevacizumab has been shown to be effective in the treatment of clear cell RCC. […]

read more

ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer

Results from this trial for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a combination of savolitinib (MET […]

read more

ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Professor Thomas Powles from the Barts Cancer Institute in London presented the results from KEYNOTE-426, a global, open-label, phase 3 study to assess the efficacy and safety of pembrolizumab plus […]

read more

ASCO GU 2019: First-line pembrolizumab shows promise in non-clear cell RCC

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. In this trial (KEYNOTE-427), treatment of patients with advanced non-clear cell renal cell carcinoma (RCC) with pembrolizumab monotherapy demonstrated an overall objective response rate of around 25% for papillary RCC […]

read more
Showing 21 to 30 of 483 results
  TOP